Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.
about
ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in uteroEarly Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature MouseOseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Factors affecting drug-induced liver injury: antithyroid drugs as instances.Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.Paediatric pharmacokinetics: key considerations.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Developmental Regulation of Drug-Processing Genes in Livers of Germ-Free MiceEffects of leukotriene receptor antagonists on peripheral eosinophil counts and serum IgE levels in children with food allergy.Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics.Crosstalk between xenobiotics metabolism and circadian clock.Tissue distribution and proinflammatory cytokine gene expression following acute oral exposure to deoxynivalenol: comparison of weanling and adult mice.Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsPharmacokinetics in special populations.Ambient tonicity and intestinal cytochrome CYP3A.The role of circadian timing system on drug metabolism and detoxification.Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control.Antipsychotic drug toxicology in children.Pharmacokinetics and metabolism update for some recent antipsychotics.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Ontogeny of oral drug absorption processes in children.Pediatric drug development: formulation considerations.Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective.Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.Biopharmaceutic planning in pediatric drug development.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.Safety issues with ethanol as an excipient in drugs intended for pediatric use.Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures.
P2860
Q27303845-D8F823EC-73FA-4F63-AD1C-C4D5513B7428Q27340373-49407FC9-F25D-41EA-B3BF-FBA8D21018F9Q30409023-A697E4FD-D084-4422-BB0F-ED81932CF540Q34339590-590C4F12-9254-4D7E-A594-0C29F1CA48F0Q34626408-9EFC4DBC-E504-4505-AD84-79C9668C2900Q35135940-AEA0948E-CDB8-4E12-ACEA-3A1BC2603B5CQ35197257-32709643-76D6-486F-BD0E-97CCF1FDB4CCQ36027794-4F6E9AD3-E6EE-4D23-8CA4-6CB68015075AQ36650141-C72E8A44-FA42-4967-9F8C-BDECAB4363DEQ36662870-D1D18079-5EFA-43BE-92F5-D34807C3A0ABQ36798718-FD2F6454-1AB8-4FAA-948C-A113FBD808A4Q37050091-CB573473-ACC6-45AC-8D28-4302E93C8A64Q37378093-5D944831-21E6-44C7-A4E9-570D7B28B771Q37550561-5E0DBC9B-6457-465C-B776-93D9BBD86B93Q37725997-7451ECB3-FA00-4C17-9AE4-DEED9933377AQ37824710-323137E3-CC97-49F5-88C8-B4CD0377222CQ37846890-7D046D13-0A65-4454-992D-C4106F324B7EQ37852719-D6F553E4-502A-484B-A81E-8FEC885B8819Q37863118-69C320E8-0F9F-44A2-B877-9BF6EB588120Q37872786-8A1FB538-390D-4A29-AFF5-B2C098ADD3C5Q38017723-0CC4D3C8-6348-4416-A4E0-4D31A736BD8BQ38183868-FDE17A33-E18B-45B8-86DE-EF461AD79943Q38263127-6BC1F41C-1E28-4071-9E17-6DD0CFED5790Q38291356-9CF6682A-30D7-404D-8334-13561C895CEFQ38357598-9419F157-09DA-4BEC-8AC3-79DB0A2BC93EQ38852053-888AC21C-8B04-4A92-9876-7E3F18CC2F16Q38951196-5429432B-45CC-445E-BDA7-24153C22C16DQ40267874-5C0B7397-B00A-44CE-88BD-0D6F54CD564CQ42182483-E81018B7-7CFE-453D-8EA4-DA44BB04F0BAQ42720364-D947D09F-B6F6-41B6-9CA2-CC524C3B9B2AQ47318170-5FFF0367-49F6-4E55-AC21-1E3AA8037639Q50593909-4C54B4F1-973F-4E62-9C30-60BB02031473Q55054084-08B52041-2AD2-4B74-A91A-4E3CF5C5A0C7Q55602133-0791FAB2-73AC-4134-989B-26F7A14E8356
P2860
Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Differences in absorption, dis ...... diatric and adult populations.
@ast
Differences in absorption, dis ...... diatric and adult populations.
@en
type
label
Differences in absorption, dis ...... diatric and adult populations.
@ast
Differences in absorption, dis ...... diatric and adult populations.
@en
prefLabel
Differences in absorption, dis ...... diatric and adult populations.
@ast
Differences in absorption, dis ...... diatric and adult populations.
@en
P2093
P2860
P356
P1476
Differences in absorption, dis ...... diatric and adult populations.
@en
P2093
Strolin Benedetti M
Whomsley R
P2860
P304
P356
10.1517/17425255.1.3.447
P407
P577
2005-10-01T00:00:00Z